For the quarter ending 2025-09-30, LYEL made $15K in revenue. -$38,702K in net income. Net profit margin of -258013.33%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue | 15 | 8 | 7 | 34 |
| Research and development | 28,172 | 34,857 | 43,447 | 39,500 |
| General and administrative | 10,687 | 9,786 | 14,046 | 11,769 |
| Other operating income, net | 1,591 | -1,062 | 119 | 730 |
| Impairment of long-lived assets | 0 | 1,443 | - | - |
| Total operating expenses | 37,268 | 47,148 | 57,374 | 50,539 |
| Loss from operations | -37,253 | -47,140 | -57,367 | -50,505 |
| Interest income, net | 3,266 | 3,276 | 3,862 | 5,965 |
| Other (expense) income, net | -4,859 | 1,180 | 1,310 | -43 |
| Impairment of other investments | 0 | 0 | - | - |
| Total other (loss) income, net | -1,593 | 4,456 | 5,172 | 5,922 |
| Net loss | -38,846 | -42,684 | -52,195 | -44,583 |
| Net unrealized gain (loss) on marketable securities | 144 | -101 | -133 | 1,157 |
| Comprehensive loss | -38,702 | -42,785 | -52,328 | -43,426 |
| Net loss per common share, basic (in dollars per share) | -2.13 | -2.89 | -0.18 | -0.17 |
| Net loss per common share, diluted (in dollars per share) | -2.13 | -2.89 | -0.18 | -0.17 |
| Weighted-average shares used to compute net loss per common share, basic (in shares) | 18,268,000 | 14,793,000 | 295,098,000 | 256,309,000 |
| Weighted-average shares used to compute net loss per common share, diluted (in shares) | 18,268,000 | 14,793,000 | 295,098,000 | 256,309,000 |
Lyell Immunopharma, Inc. (LYEL)
Lyell Immunopharma, Inc. (LYEL)